Stomach acid in which some have too much hence the use of antacids etc.

If I understood correctly, Dac is just slightly better than Led in types 1 and 4. And we already knew that type 3 has to use Dac.

So the evidence is in …

Daclatasvir is the pan-genotypic choice.

And now AbbVie is getting high success rates WITHOUT Sofosbuvir !!!
http://www.prnewswire.com/news-releases/abbvies-investigational-pan-genotypic-regimen-of-abt-493-and-abt-530-shows-high-svr-rates-in-genotype-1-hepatitis-c-patients-who-failed-previous-therapy-with-direct-acting-antivirals-300252074.html

Let the price competition begin!

Treatment of GT1 in Denmark: Genotype 1 without cirrhosis

Hi James Freemann

For your information:

(1st choice to min. 70% of
Population) February 2017

Here is what the Danish health authorities recommend if they are offered treatment in Denmark

Viekirax® (ombitasvir 12.5 mg + paritaprevir
75 mg + ritonavir 50 mg) 2 tablets 1 x
Daily for 12 weeks
+
Exviera® (dasabuvir 250 mg) 2 x daily in 12
weeks
+
Ribavirin 2 x daily for 12 weeks

Before, there were 6 different treatment proposals, all of which were equal:

Genotype 1 without cirrhosis
Use as 1st choice for
mine. 70% off
population
(Genotype 1) Sep 2016:
(Strong recommendation for)
Sofosbuvir (400 mg) + ledipasvir (90 mg) 1 x daily
For 8-12 weeks *
or
Sofosbuvir 1 x daily (400 mg) and simprevir 1 x daily
(150 mg) for 12 weeks
or
Sofosbuvir 1 x daily (400 mg) and daclatasvir 1 x daily
(60 mg) for 12 weeks
or
Ombitasvir (12.5 mg) + paritaprevir (75 mg) + ritonavir
(50 mg) 2 tablets 1 x daily and dasabuvir (250 mg)
2 x daily for 12 weeks **
or
Sofosbuvir (400 mg) + velpatasvir (100 mg) 1 x daily
For 12 weeks
or
Elbasvir (50 mg) + grazoprevir (100 mg) 1 x daily for 12
week ***

Greeting
Gert